+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are assessing the long-term safety of subcutaneous guselkumab in children with moderate to severe ulcerative colitis, Crohns disease, or juvenile psoriatic arthritis. This Phase 3, open-label study enrolls pediatric participants who previously received guselkumab in one of three primary studies and are considered by their investigator to benefit from continued treatment. The study aims to monitor safety over an extended period to better understand the effects of ongoing guselkumab use in these conditions. Participants who completed dosing in the primary studies will continue guselkumab treatment in this long-term extension study. Dosing schedules include injections every 8 weeks or every 4 weeks, depending on their original study arm and clinical status. Some participants may switch dosing intervals once during the study before unblinding, while others will maintain their initial regimen. The study allows continued access to guselkumab over the long term, with dosing adjustments guided by prior treatment plans and investigator discretion. Throughout the study, participants will be closely monitored for treatment-emergent adverse events for up to 6 years and 9 months. Assessments will include regular evaluations by investigators to ensure safety and adherence. Parents or legal representatives consent for children to participate, with assent obtained from capable participants aged 7 years and older. The study emphasizes long-term safety tracking and maintaining participant well-being during extended guselkumab therapy.

Age: 3Years +All GendersPhase 3
53 locations
O

Actively Recruiting

Researchers are evaluating MAS825 arumakimig in a phase II trial to study its clinical efficacy, safety, and tolerability in both pediatric and adult participants with Stills disease. This trial includes individuals who have had an inadequate response to IL-1, IL-6, or other available therapies. Participants with associated lung disease or macrophage activation syndrome may also join the study, which lasts approximately 16 months across multiple centers. Participants receive MAS825 in an open-label, single-arm design with no placebo group. The study consists of three periods Screening, Treatment Period 1, and Treatment Period 2. The treatment aims to assess response based on clinical criteria and biomarker levels. The drug is administered under medical supervision, and participants are monitored throughout the trial. During the study, participants undergo various assessments including clinical response evaluations on Day 85, biomarker measurements, physician assessments, and quality of life questionnaires. The study also tracks changes in glucocorticoid dose and disease activity over up to 15 months. Safety and tolerability are closely monitored, and the total participation time spans about 16 months from screening through treatment and follow-up.

Age: 1Year +All GendersPhase 2
23 locations
O

Actively Recruiting

Researchers are evaluating the drug sarilumab in children and adolescents aged 1 to 17 years with Systemic Juvenile Idiopathic Arthritis sJIA. The study aims to describe how sarilumab behaves in the body pharmacokinetics, its effects pharmacodynamics, efficacy, and long-term safety in this population to determine an appropriate dose and treatment regimen. This is a Phase 2 open-label trial sponsored by Sanofi. Participants will receive one of two ascending doses or an additional intermediate dose of sarilumab by subcutaneous injection based on body weight. The selected dose will be administered once identified. Treatment begins with a 12-week core phase followed by a 144-week extension phase during which sarilumab continues to be given. After treatment, there is a 6-week post-treatment follow-up. Throughout the 166-week total study duration, participants will be monitored with various assessments including blood tests to measure drug levels and disease activity, evaluations of adverse events, and questionnaires to assess well-being and symptoms. Measurements like juvenile arthritis response rates and disease activity scores are tracked during both the core and extension phases. Safety, including injection site reactions and changes in glucocorticoid use, is also followed closely.

Age: 1Year - 17YearsAll GendersPhase 2
40 locations
S

Actively Recruiting

Researchers are evaluating baricitinib to see if it can preserve beta-cell function in children and adults newly diagnosed with type 1 diabetes. This Phase 3 randomized, double-blind, placebo-controlled study includes participants aged 1 to under 36 years who have been recently diagnosed with type 1 diabetes. The study aims to understand the impact of baricitinib on insulin-producing cells to potentially support better diabetes management. Participants will be randomly assigned to receive either oral baricitinib or a placebo. The treatment period lasts up to 52 weeks, during which participants will take their assigned study medication regularly. The study compares the effects of baricitinib against placebo to assess preservation of beta-cell function and related outcomes. Throughout the approximately 60-week participation, individuals will undergo multiple assessments including measuring C-peptide levels, hemoglobin A1c, insulin use, hypoglycemic events, growth parameters, and quality of life surveys. Safety and drug levels will also be monitored. These evaluations help researchers determine how the study drug affects diabetes control and participant health over time.

Age: 1Year - 35YearsAll GendersPhase 3
130 locations
L

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the drug baricitinib for treating Juvenile Idiopathic Arthritis JIA in children and adolescents aged 1 to less than 18 years. This Phase 3 study focuses on participants who have already taken part in previous baricitinib studies for JIA to understand long-term effects. Participants receive baricitinib orally as the study treatment. This is a single-group study, meaning all participants will take baricitinib without comparison to a placebo or other drugs. The study follows participants for up to 264 weeks about 5 years to monitor treatment effects and safety over a long period. During the study, researchers will track serious adverse events, any permanent stops of baricitinib, and various measures of disease activity, pain, and skin condition related to JIA. These include assessments like the Pediatric American College of Rheumatology response index and Juvenile Arthritis Disease Activity Score. Participants will be monitored regularly throughout the study to evaluate health and immune responses while taking the study drug.

Age: 1Year - 18YearsAll GendersPhase 3
77 locations
S

Actively Recruiting

Researchers are studying juvenile psoriatic arthritis jPsA, a condition where the immune system attacks healthy joints causing pain, stiffness, and swelling. This trial evaluates the safety of risankizumab and its effect on disease symptoms in children and adolescents with jPsA. The study compares risankizumab to adalimumab, a treatment already approved for jPsA, aiming to assess improvements and side effects. Participants aged 5 to 17 years with active jPsA will be randomly assigned to receive either risankizumab or adalimumab through subcutaneous injections based on body weight. The study consists of two periods Period 1 lasts 24 weeks where participants receive the assigned treatment. Those who respond will continue the same treatment for an additional 100 weeks in Period 2. After treatment ends, participants receiving risankizumab will have a 140-day safety follow-up, while those on adalimumab will have a 70-day follow-up. During the trial, participants will attend regular hospital or clinic visits for medical assessments, blood tests, monitoring for side effects, and completing questionnaires. Researchers will measure improvements in arthritis symptoms using standardized response criteria and monitor adverse events up to 144 weeks. The study aims to gather detailed information on disease activity, treatment response, and safety over approximately two and a half years.

Age: 5Years - 17YearsAll GendersPhase 3
34 locations
E

Actively Recruiting

Researchers are evaluating the pharmacokinetics, pharmacodynamics, efficacy, and safety of anifrolumab infusion compared with placebo in children aged 5 to under 18 years with moderate to severe active systemic lupus erythematosus SLE who are on standard background therapy. This phase III study aims to better understand how anifrolumab works and its effects in pediatric SLE patients. Participants are randomly assigned to receive either anifrolumab or a matching placebo via intravenous infusion every 4 weeks. The study includes multiple periods a screening period up to 30 days Part A, a four-week double-blind, placebo-controlled pharmacokinetic phase Part B, a double-blind, placebo-controlled safety and efficacy phase lasting 48 to 52 weeks depending on prior participation Part C, a 52-week open-label extension and Part D, a safety follow-up with one visit 12 weeks after the last dose. During the study, participants undergo various assessments including blood tests to measure drug levels, immune markers, and disease activity using specific lupus assessment tools. Researchers monitor response to treatment, safety, and changes in corticosteroid use over time. The total participation lasts about 116 weeks, with scheduled visits for infusions and evaluations to track disease progress and treatment effects.

Age: 5Years - 17YearsAll GendersPhase 3
103 locations
O

Actively Recruiting

Researchers are evaluating the levels of plasma bimekizumab after subcutaneous administration in children aged 2 to under 18 years with active juvenile idiopathic arthritis subtypes, specifically enthesitis-related arthritis including juvenile-onset ankylosing spondylitis and juvenile psoriatic arthritis. This Phase 3 open-label trial aims to understand the pharmacokinetics and safety of bimekizumab in this pediatric population. Participants will receive weight-based doses of bimekizumab at scheduled times. The study is a single-arm design where all participants receive the investigational drug. The initial treatment period lasts up to 16 weeks, during which plasma concentrations of bimekizumab are monitored closely. Following this, there is a safety follow-up period lasting up to 141 weeks to track treatment-emergent adverse events and other safety parameters. Throughout the study, participants will undergo various assessments including vital signs, blood tests for biochemistry and hematology, growth measurements, and evaluations for injection site pain. Disease activity and response are measured using standardized pediatric arthritis scores. Researchers will also monitor for antibodies against bimekizumab and record any serious or specific safety events. The total participation may extend over several years to ensure long-term safety and treatment effects are observed.

Age: 2Years - 18YearsAll GendersPhase 3
23 locations
E

Actively Recruiting

Researchers are evaluating the efficacy of apremilast compared with placebo in treating active juvenile psoriatic arthritis JPsA in children aged 5 to under 18 years. This phase 3, multicenter, double-blind, randomized, placebo-controlled study aims to assess the effects of apremilast on disease activity in this pediatric population. Participants will be randomly assigned to receive either apremilast or a matching placebo orally during the 16-week double-blind treatment phase. After this, all participants will continue treatment with apremilast during a 36-week active treatment phase. The study uses a parallel group design and evaluates multiple outcomes related to joint activity, pain, well-being, and inflammation. Throughout the study, participants will undergo assessments including joint counts, pain evaluation, physician global assessments, and laboratory tests such as C-reactive protein levels. Researchers will also monitor safety through treatment-emergent adverse events and suicidal ideation assessments. Pharmacokinetics of apremilast and growth parameters like body weight, height, and Tanner staging will be evaluated. Total participation may last up to 56 weeks.

Age: 5Years - 17YearsAll GendersPhase 3
44 locations
I

Actively Recruiting

This research aims to improve treatment for children and adolescents newly diagnosed with lymphoblastic lymphoma. The trial is a large, international, randomized clinical study involving multiple countries and specialized centers. It focuses on whether using dexamethasone instead of prednisone during the induction phase can reduce relapses in the central nervous system CNS, and for high-risk patients, whether an intensified treatment improves event-free survival compared to standard therapy. Participants are grouped by risk level based on disease characteristics like CNS involvement and genetic markers. All patients first receive a prednisone prephase, then are randomized to either standard induction with prednisone or experimental induction with dexamethasone. Treatment phases include consolidation, extra-compartment phases adjusted by risk group, reintensification for some groups, and maintenance therapy lasting up to 24 months. Patients with CNS involvement receive intensified intrathecal therapy without cranial irradiation. High-risk patients may undergo a second randomization to receive either standard or intensified treatment during later phases. During the study, patients undergo various treatments including chemotherapy drugs such as cyclophosphamide, methotrexate, and PEG asparaginase. Researchers monitor disease relapse involving the CNS and measure event-free survival over a maximum of 7.25 years. Secondary assessments include overall survival, treatment-related toxicity and mortality, adverse events, and molecular markers. The trial involves ongoing follow-up for safety and effectiveness outcomes throughout the study period, which can last several years.

Age: 0 - 18YearsAll GendersPhase 3
228 locations

1-10 of 15

1